Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune Inc.
Replimune Inc.
Myeloid Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Mayo Clinic
Daiichi Sankyo
Compugen Ltd
Eli Lilly and Company
Astellas Pharma Inc
OHSU Knight Cancer Institute
Fate Therapeutics
Fate Therapeutics
Bristol-Myers Squibb
Celgene